Curated news and analysis on clinical trials, drug approvals, and medical research.
Vancouver police seized over $79,000 in illicit drugs, cash, and weapons during a six-month investigation called "Project Bingo" targeting drug trafficking on the Downtown Eastside. The search uncovered fentanyl, cocaine, methamphetamine, dilaudid pills, illegal cigarettes, and a large cache of weapons. A 61-year-old man was arrested and released pending further investigation.
A case series of three Erdheim-Chester disease patients demonstrates the disease's diagnostic challenges, with one patient improving on targeted BRAF inhibition while two others died within a year. The rare histiocytosis often presents with multisystem involvement, delaying diagnosis.
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
UC Davis received a $5 million Gates Foundation grant to expand self-cloning crops to other staple foods. Congress approved continued NIH and NSF funding, maintaining similar levels to the previous year. Faculty and students emphasized federal funding's role in supporting basic research and training scientists.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
Clover Hill Dairy recalled requesón/soft ricotta cheese on June 3, 2026, over potential Listeria contamination, with products sold in New York and Virginia. Listeria causes approximately 1,250 U.S. cases annually with an 86% hospitalization rate, and poses severe risks to pregnant women including pregnancy loss and stillbirth. Health officials advise pregnant individuals to avoid raw milk products, soft cheeses, deli meats, and hot dogs.
Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.
Real-world studies show early complete response after CAR T-cell therapy predicts sustained remission in large B-cell lymphoma, while historical chemotherapy yields poor outcomes in high-risk patients. Data from registries highlight a significant event-free survival advantage for second-line axicabtagene ciloleucel versus standard-of-care salvage therapy.
A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
Manitoba is developing nurse-to-patient ratios to address nurse vacancy rates as high as 50% at some sites, while Saskatchewan has hired over 2,800 nursing graduates since 2023 and expanded nursing education seats. Both provinces are implementing recruitment and retention initiatives to strengthen their nursing workforces.
New research presented at the ERA Congress found DCCB blood pressure medications were associated with a 33% increased risk of major adverse kidney events in Type 2 diabetes patients also receiving RAS and SGLT2 inhibitors. A separate study revealed that diabetic nephropathy patients exhibit the most severe biochemical disturbances, including markedly elevated glycemic indices and significantly impaired renal function compared to other groups.
Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.
AI algorithms can now detect subtle EEG abnormalities linked to genetic epilepsy without capturing active seizures, according to a University of Delaware study. At the AAN 2026 meeting, experts outlined AI applications in clinical decision support, ambient scribing, and trial recruitment, while emphasizing clinicians must maintain independent judgment.
Colorado's Prescription Drug Affordability Board imposed a price cap on Enbrel, making it the first U.S. state to cap a specific drug's price. Amgen is suing to block the cap, arguing it interferes with federal patent law protections for innovative drugs. The federal court is considering whether to issue a temporary injunction, with a ruling expected soon.
Servier will acquire Edgewise Therapeutics' muscular dystrophy business, including the drug sevasemten, for up to $2.65 billion. Sevasemten recently faced an FDA rejection for accelerated approval in Becker muscular dystrophy but is advancing to a Phase 3 trial in 2026. The drug has received multiple FDA and EMA designations for both Becker and Duchenne muscular dystrophy.
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
Two new interchangeable Lucentis biosimilars — Lupin's Ranluspec and Formycon/Bioeq's Nufymco — have received FDA approval, while Xbrane's Lucamzi is under review with an October target date. The Lucentis global market was valued at $630 million in 2024.
The US is intensifying its response to New World screwworm as confirmed cases approach within 62 miles of the US-Mexico border. Emergency exemptions allow import of new treatments from Brazil, while sterile fly releases are expanded and a $100 million research initiative is launched. All southern ports of entry remain closed to livestock trade.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
